"Midkine has assets that includes Lyramid which has a potential value of $10.8 million"
This the value for MK. As an asset its only worth what it cost us to develop to get it to this stage.
However in the markets eye its worth $10.8m as this what a buyer wanted to pay for it. NOW this could be a good price or a low valutaion (fire sale price) to complete the deal and leave some meat on the bone for Pleiades.
Now the question us have we stopped development of MK whislt in the sale process or have we been working it (will change value)
Even valued at 50% of $10.8m its 2.5p per share approx.
Going forward its time to unlock precieved value in these assets.
Leave you with this ' our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round'